A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland by Tämer El Saadany, Judith Lupatsch, Michael Mark, Michaela Barbier, Tarun Mehra, Matthias Schwenkglenks, Roger von Moos

Get full text

Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK) by Benjamin Kasenda, Miklos Pless, Beat Thürlimann, Stefanie Hayoz, Annina Lea Schenker, Christoph Kopp, Sämi Schär, Roger von Moos

Get full text

Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer. by Tarun Mehra, Judith E Lupatsch, Thibaud Kössler, Konstantin Dedes, Alexander Reinhard Siebenhüner, Roger von Moos, Andreas Wicki, Matthias E Schwenkglenks

Get full text

Correction: Olaparib not cost-effective as maintenance therapy for platinum-sensitive, BRCA1/2 germline-mutated metastatic pancreatic cancer. by Tarun Mehra, Judith E Lupatsch, Thibaud Koessler, Konstantin Dedes, Alexander Reinhard Siebenhüner, Roger von Moos, Andreas Wicki, Matthias E Schwenkglenks

Get full text

Swiss Recommendations for Systemic Therapies in Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma by Mirijam Nägeli, Joanna Mangana, Roger von Moos, Lukas Flatz, Robert E. Hunger, Rastine Merat, Olivier Gaide, Marco Siano, Reinhard Dummer

Get full text

The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma by Johanna Mangana, Berna C. Özdemir, Daniela Mihic-Probst, Marco Siano, Yannis Metaxas, Lara Valeska Maul, Robert E. Hunger, Nicole Lindenblatt, Radu Olariu, Roger von Moos, Panagiotis Balermpas, Luis Schiappacase, Cristina Mangas, Olivier Michielin, Reinhard Dummer

Get full text